AVP and Hyponatremia: Sekiya et al. showed a patient who developed hyponatremia due to CBZ administration, noting suppressed plasma AVP levels and high urine cyclic adenosine monophosphate (cAMP)/osmolality, highlighting the cAMP-dependent action of CBZ via the V2 receptor on collecting ducts [29].